Promotion of insulin-like growth factor-I production by sensory neuron stimulation; molecular mechanism(s) and therapeutic implications.
Insulin-like growth factor-I (IGF-I) plays various important roles in cellular proliferation, differentiation, survival and functions of the cell, thereby contributing to the maintenance of tissue integrity. Although it is well known that growth hormone (GH) increases serum IGF-I levels by stimulating the hepatic production, little is known about the mechanism by which local production of IGF-I in individual tissues is regulated. Stimulation of sensory neurons by capsaicin increases tissue levels of IGF-I and IGF-I mRNA in various organs via increased calcitonin gene-related peptide (CGRP) release in mice. This sensory neuron-mediated IGF-I production contributes to reducing reperfusion-induced liver injury through prevention of apoptosis in mice. Isoflavone, a phytoestrogen, increases CGRP production by increasing its transcription in sensory neurons. Administration of capsaicin and isoflavone increases IGF-I production in hair follicles, thereby promoting hair growth in mice and in volunteers with alopecia. Topical application of capsaicin increases dermal levels of IGF-I by stimulating sensory neurons in mice and increases facial skin elasticity in humans. Plasma and tissue levels of CGRP and IGF-I in spontaneously hypertensive rats (SHR) are lower than those in normotensive Wistar Kyoto rats (WKY), contributing to the development of hypertension, heart failure and insulin resistance in SHR. Administration of capsaicin increases CGRP and IGF-I levels in plasma, kidneys and the heart in SHR to WKY levels, and normalizes mean arterial blood pressure in SHR. Since administration of GH or IGF-I has some deleterious effects, pharmacological stimulation of sensory neurons leading to increased tissue IGF-I levels might be a novel therapeutic strategy for various pathologic conditions.
Okajima
Kenji
K
Department of Translational Medical Science Research, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. whynot@med.nagoya-cu.ac.jp
Harada
Naoaki
N
D000818:Animals; D000991:Antithrombins / Q000494:pharmacology / Q000627:therapeutic use; D049109:Cell Proliferation / Q000187:drug effects; D004358:Drug Therapy; D013006:Growth Hormone / Q000494:pharmacology; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000096:biosynthesis* / Q000502:physiology; D009752:Nutritional Status; D011984:Sensory Receptor Cells / Q000378:metabolism* / Q000502:physiology*; D015842:Serine Proteinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D013268:Stimulation, Chemical
D000991:Antithrombins; D015842:Serine Proteinase Inhibitors; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone